このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Aclarion マネジメント

マネジメント基準チェック /44

現在、CEO に関する十分な情報がありません。

主要情報

Brent Ness

最高経営責任者

US$300.0k

報酬総額

CEO給与比率	100.0%
CEO在任期間	3yrs
CEOの所有権	0.01%
経営陣の平均在職期間	3yrs
取締役会の平均在任期間	3yrs

経営陣の近況

Recent updates

CEO報酬分析

Aclarion の収益と比較して、Brent Ness の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	-US$6m
Mar 31 2024	n/a	n/a	-US$6m
Dec 31 2023	US$300k	US$300k	-US$5m
Sep 30 2023	n/a	n/a	-US$5m
Jun 30 2023	n/a	n/a	-US$5m
Mar 31 2023	n/a	n/a	-US$7m
Dec 31 2022	US$509k	US$300k	-US$7m
Sep 30 2022	n/a	n/a	-US$8m
Jun 30 2022	n/a	n/a	-US$9m
Mar 31 2022	n/a	n/a	-US$6m
Dec 31 2021	US$526k	US$100k	-US$6m

報酬と市場: Brentの総報酬 ($USD 300.00K ) は、 US市場 ($USD 673.68K ) の同様の規模の企業の平均を下回っています。

報酬と収益: Brentの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Brent Ness (57 yo)

3yrs

在職期間

US$300,000

報酬

Mr. Brent Ness has been President of Aclarion, Inc. (fka Nocimed, Inc.) since October 1, 2021 and its Chief Executive Officer & Director since September 15, 2021. From December 2019 to April 2021, Mr. Ness...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Jeffrey Thramann	Executive Chairman	4yrs	US$300.00k	0% $ 0
Brent Ness	CEO, President & Director	3yrs	US$300.00k	0.014% $ 225.2
John Lorbiecki	Chief Financial Officer	2.9yrs	US$225.00k	0.015% $ 246.1
Ryan Bond	Chief Strategy Officer	3yrs	US$200.00k	0.014% $ 219.7

3.0yrs

平均在職期間

58yo

平均年齢

経験豊富な経営陣: ACONの経営陣は経験豊富であると考えられます ( 2.7年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Jeffrey Thramann	Executive Chairman	4yrs	US$300.00k	0% $ 0
Brent Ness	CEO, President & Director	3yrs	US$300.00k	0.014% $ 225.2
William Wesemann	Lead Independent Director	8.7yrs	US$40.00k	0.036% $ 579.5
Jeffrey Lotz	Member of Scientific Advisory Board	no data	US$12.86k	データなし
Stephen Deitsch	Independent Director	2.4yrs	US$45.00k	0% $ 0
Scott Breidbart	Independent Director	2.4yrs	US$40.00k	0% $ 0
Robert Eastlack	Member of Medical Advisory Board	no data	US$14.77k	データなし
David Neal	Director	8yrs	US$25.00k	0.13% $ 2.0k
Amanda Williams	Independent Director	2.4yrs	US$35.00k	0% $ 0
Lawrence Tannenbaum	Member of Medical Advisory Board	no data	US$10.40k	データなし

3.0yrs

平均在職期間

58yo

平均年齢

経験豊富なボード: ACONの取締役会は経験豊富であると考えられます ( 3年の平均在任期間)。

Aclarion マネジメント

マネジメント 基準チェック /44

主要情報

経営陣の近況

Aclarion, Inc., Annual General Meeting, Dec 18, 2023

Aclarion, Inc., Annual General Meeting, Dec 18, 2023

High number of new and inexperienced directors

Aclarion, Inc. George Frey MD as Key Opinion Leader

Aclarion, Inc’s Key Opinion Leader Program Adds Fifth Surgeon Advisor with Addition of Eric Potts, MD

High number of new directors

Recent updates

Aclarion's Nociscan AI Plays Key Role in Advanced Understanding of Modic Changes

Aclarion, Inc. has filed a Follow-on Equity Offering in the amount of $1.075 million.

Aclarion Launches Surgeon Partnership to Apply Nociscan's Ai Technology to Personal Injury and Workers Compensation Market

Aclarion Receives Non-Compliance Letter from Nasdaq Due to Non-Compliance with the Nasdaq Minimum Stockholders’ Equity Requirement

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: US$0.44 loss per share (vs US$2.39 loss in 1Q 2023)

Aclarion Receives Notice from Nasdaq Regarding Non-Compliance with the $1.00 Minimum Bid Price Requirement Set Forth in Nasdaq Listing Rule 5550(a)(2)

Aclarion, Inc. has completed a Composite Units Offering in the amount of $3.0015 million.

Full year 2023 earnings released: US$8.82 loss per share (vs US$19.61 loss in FY 2022)

Aclarion Announces Updated Product Release That Expands Mri Scanner Access for Nociscan Solution

New major risk - Shareholder dilution

Aclarion, Inc. announced that it has received $0.25 million in funding

Third quarter 2023 earnings released: US$0.12 loss per share (vs US$0.21 loss in 3Q 2022)

Aclarion, Inc., Annual General Meeting, Dec 18, 2023

Aclarion, Inc., Annual General Meeting, Dec 18, 2023

Nasdaq Staff Determines to Delist the Aclarion Common Stock from Nasdaq, Unless the Company Timely Requests an Appeal of the Staff’s Determination to A Hearings Panel

Nasdaq Confirms Aclarion Regains Compliance with Rule 5250(c)(1) Regarding Filing of 10-Q Report

Aclarion Announces Update on Non-Compliance Notice from Nasdaq Regarding Late Filing of 10-Q Report

High number of new and inexperienced directors

Aclarion Receives Non-Compliance Notice From Nasdaq

Aclarion, Inc. Regains Compliance with Nasdaq

Aclarion, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement

Aclarion, Inc. Receives Nasdaq Notice Regarding Late Filing of 10-Q Report

Aclarion, Inc. announced delayed 10-Q filing

Full year 2022 earnings released: US$1.25 loss per share (vs US$6.58 loss in FY 2021)

Aclarion, Inc. George Frey MD as Key Opinion Leader

Aclarion, Inc. Receives a Written Notice from the Listing Qualifications Department of the Nasdaq Stock Market

Aclarion, Inc’s Key Opinion Leader Program Adds Fifth Surgeon Advisor with Addition of Eric Potts, MD

High number of new directors

Aclarion, Inc.'s Nociscan Selected for Inclusion in Pivotal National Institutes of Health Study for Low Back Pain

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

First quarter 2022 earnings released: US$1.35 loss per share (vs US$0.81 loss in 1Q 2021)

Director recently bought US$150k worth of stock

High number of new directors

Aclarion, Inc. has completed an IPO in the amount of $9.41775 million.

Aclarion, Inc. has completed an IPO in the amount of $9.41775 million.

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /44